• Cancer Marker Profile with thyroglobulin and CEA for differentiated thyroid cancer is done to help monitor the progression of the disease and response to treatment.
• Thyroglobulin is a protein produced by thyroid cells, and it can be used as a marker for differentiated thyroid cancer. Elevated levels of thyroglobulin may indicate the presence of recurrent or persistent disease after treatment. In patients with differentiated thyroid cancer, thyroglobulin is often used as a marker for recurrence or persistent disease after treatment. It can also be used to monitor the response to treatment, such as surgery and radioactive iodine therapy.
• CEA (carcinoembryonic antigen) is not specific to differentiated thyroid cancer, but it may be used as a marker of other cancers.

Additionally, these markers can be used to monitor the response to treatment, such as surgery and radioactive iodine therapy

• The Cancer Marker Profile with Thyroglobulin, CEA is typically done for individuals who have been diagnosed with differentiated thyroid cancer and have undergone treatment, such as surgery and radioactive iodine therapy. The test is used to monitor the progression of the disease and response to treatment.
• Patients with differentiated thyroid cancer who have had surgery to remove their thyroid gland and/or have received radioactive iodine therapy are recommended to undergo regular monitoring of thyroglobulin. This is because thyroglobulin is a protein produced by thyroid cells and elevated levels may indicate the presence of recurrent or persistent disease after treatment.
• CEA is not specific to differentiated thyroid cancer, and it is not used as a regular monitoring test. It may be done if there is a concern of other cancer.

Cancer Marker Profile for differentiated thyroid cancer measures thyroglobulin and CEA.

This test requires a blood sample. A tourniquet (elastic) band is placed tightly on the upper arm. The patient is then asked to make a fist. This helps in the build-up of blood filling the veins. The skin is disinfected before needle insertion and the blood sample is collected in vacutainer.

• If the Thyroglobulin and CEA tests are positive for thyroid cancer, it may indicate that there is recurrent or persistent disease present.
• In patients with differentiated thyroid cancer, elevated levels of thyroglobulin may indicate the presence of recurrent or persistent disease after treatment. This could mean that there are remaining cancer cells in the body, or that the cancer has come back (recurred) after initial treatment.
• If CEA is positive, it can be an indication that the patient has another cancer or could also indicate that the patient has not yet responded to treatment.